No Data
No Data
No Data
No Data
No Data
Investors Still Aren't Entirely Convinced By Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited's (SHSE:600329) Earnings Despite 25% Price Jump
Despite an already strong run, Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHSE:600329) shares have been powering on, with a gain of 25% in the last thirty days. Unfortunately, th
Simply Wall StApr 30 20:32 ET
Tianjin Pharmaceutical's Q1 Profit, Revenue Fall 3%
Tianjin Pharmaceutical Da Ren Tang's (SHA:600329) attributable profit fell 3.4% year over year to 387.3 million yuan in the first quarter, according to a Tuesday filing with the Shanghai Stock Exchang
MT NewswiresApr 30 05:58 ET
Daren Tang (600329.SH): Net profit for the first quarter was 387 million yuan, down 3.36% year on year
On April 29, Ge Longhui (600329.SH) released its report for the first quarter of 2024. During the reporting period, it achieved operating income of 2,086 billion yuan, a year-on-year decrease of 3.19%; net profit attributable to shareholders of listed companies was 387 million yuan, a year-on-year decrease of 3.36%; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 376 million yuan, a year-on-year decrease of 4.84%; and basic earnings per share were 0.50 yuan.
Gelonghui FinanceApr 29 04:07 ET
Is Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) A Risky Investment?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Simply Wall StApr 21 20:45 ET
Should You Be Adding Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) To Your Watchlist Today?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. But the reality is that when a company lo
Simply Wall StApr 3 22:51 ET
Tianjin Pharmaceutical Da Ren Tang's 2023 Profit Rises 14.5%
Tianjin Pharmaceutical Da Ren Tang's (SHA:600329) attributable profit rose 14.49% to 986.7 million yuan in 2023 from 861.8 million yuan in 2022, according to a Tuesday filing with the Shanghai bourse.
MT NewswiresApr 2 07:04 ET
No Data
No Data